| 摘要 |
<p>Methods comprising the administration of a partial fatty acid oxidation inhibitor such as ranolazine are provided for treating diabetes, lowering plasma level of HbAlc, gluclose plasma levels, total cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or a non-diabetic mammal while minimizing undesirable side effects.</p> |
